Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

BACKGROUND: In the primary analysis population (i.e., PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. Pembrolizumab had a favorable safety profile in the all-patient po...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, Eric, Amonkar, Mayur, Fuchs, Charles S., Alsina, Maria, Özgüroğlu, Mustafa, Bang, Yung-Jue, Chung, Hyun Cheol, Muro, Kei, Goekkurt, Eray, Benson, Al B., Sun, Weijing, Wainberg, Zev A., Norquist, Josephine M., Chen, Xinqun, Shih, Chie-Schin, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502140/
https://www.ncbi.nlm.nih.gov/pubmed/34363528
http://dx.doi.org/10.1007/s10120-021-01200-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502140/
https://www.ncbi.nlm.nih.gov/pubmed/34363528
http://dx.doi.org/10.1007/s10120-021-01200-w

Ejemplares similares